| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant or neoadjuvant treatment with immune checkpoint inhibitors: re-assessing the risk–benefit ratio
|
Delyon, Julie
|
|
|
25 |
1 |
p. 3-5
|
artikel
|
| 2 |
Agreement to reduce industrial emissions in Europe
|
Das, Manjulika
|
|
|
25 |
1 |
p. 20
|
artikel
|
| 3 |
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
|
Bamias, Aristotelis
|
|
|
25 |
1 |
p. 46-61
|
artikel
|
| 4 |
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
|
Grande, Enrique
|
|
|
25 |
1 |
p. 29-45
|
artikel
|
| 5 |
Australia's new cancer nursing and navigation plan
|
Das, Manjulika
|
|
|
25 |
1 |
p. 18
|
artikel
|
| 6 |
Carcinogenicity of perfluorooctanoic acid and perfluorooctanesulfonic acid
|
Zahm, Shelia
|
|
|
25 |
1 |
p. 16-17
|
artikel
|
| 7 |
Commercial determinants of cancer
|
The Lancet Oncology,
|
|
|
25 |
1 |
p. 1
|
artikel
|
| 8 |
Correction to Lancet Oncol 2020; 21: 671–84
|
|
|
|
25 |
1 |
p. e3
|
artikel
|
| 9 |
Correction to Lancet Oncol 2024; 25: e6–17
|
|
|
|
25 |
1 |
p. e3
|
artikel
|
| 10 |
Cumulative incidence of second primary cancers in a large nationwide cohort of Danish cancer survivors: a population-based retrospective cohort study
|
Kjaer, Trille Kristina
|
|
|
25 |
1 |
p. 126-136
|
artikel
|
| 11 |
Dignity and inequality at the end of life
|
Stirrups, Robert
|
|
|
25 |
1 |
p. 26-28
|
artikel
|
| 12 |
Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial
|
Cuzick, Jack
|
|
|
25 |
1 |
p. 108-116
|
artikel
|
| 13 |
Evolution of front-line immunotherapy for metastatic urothelial cancer
|
Siefker-Radtke, Arlene O
|
|
|
25 |
1 |
p. 2-3
|
artikel
|
| 14 |
FDA investigates risk of secondary lymphomas after CAR-T immunotherapy
|
Furlow, Bryant
|
|
|
25 |
1 |
p. 21
|
artikel
|
| 15 |
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
|
Song, Yuqin
|
|
|
25 |
1 |
p. 117-125
|
artikel
|
| 16 |
Is there finally a place for neoadjuvant treatment in locally advanced cervical cancer?
|
Pautier, Patricia
|
|
|
25 |
1 |
p. 5-6
|
artikel
|
| 17 |
Liver MRI in patients scheduled for local therapy of colorectal liver metastases
|
Vernuccio, Federica
|
|
|
25 |
1 |
p. 9-10
|
artikel
|
| 18 |
Measures to improve cancer situation in Cyprus
|
Das, Manjulika
|
|
|
25 |
1 |
p. e4
|
artikel
|
| 19 |
Mitotane and the myth of 14 mg/L
|
Ehrlich, Matthew I
|
|
|
25 |
1 |
p. 12-15
|
artikel
|
| 20 |
Morphine manifesto seeks to boost access to oral morphine
|
Sharma, Dinesh C
|
|
|
25 |
1 |
p. e5
|
artikel
|
| 21 |
Mortality from leading cancers in districts of England from 2002 to 2019: a population-based, spatiotemporal study
|
Rashid, Theo
|
|
|
25 |
1 |
p. 86-98
|
artikel
|
| 22 |
MRI in addition to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): an international, multicentre, prospective, diagnostic accuracy trial
|
Görgec, Burak
|
|
|
25 |
1 |
p. 137-146
|
artikel
|
| 23 |
Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial
|
Li, Kezhen
|
|
|
25 |
1 |
p. 76-85
|
artikel
|
| 24 |
New French national tobacco control programme
|
Casassus, Barbara
|
|
|
25 |
1 |
p. 22
|
artikel
|
| 25 |
New Zealand backtracks on antismoking laws
|
Kirby, Tony
|
|
|
25 |
1 |
p. 19
|
artikel
|
| 26 |
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
|
Hofman, Michael S
|
|
|
25 |
1 |
p. 99-107
|
artikel
|
| 27 |
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group
|
Albert, Nathalie L
|
|
|
25 |
1 |
p. e29-e41
|
artikel
|
| 28 |
Serum hormone concentrations and individualisation of breast cancer prevention
|
Chumsri, Saranya
|
|
|
25 |
1 |
p. 8-9
|
artikel
|
| 29 |
Shortages of essential cancer medicines: who is responsible and what are the possible solutions?
|
Jenei, Kristina
|
|
|
25 |
1 |
p. 23-26
|
artikel
|
| 30 |
Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)
|
Siva, Shankar
|
|
|
25 |
1 |
p. e18-e28
|
artikel
|
| 31 |
The future of cancer care in the UK—time for a radical and sustainable National Cancer Plan
|
Aggarwal, Ajay
|
|
|
25 |
1 |
p. e6-e17
|
artikel
|
| 32 |
Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials
|
Fujiwara, Yu
|
|
|
25 |
1 |
p. 62-75
|
artikel
|
| 33 |
Universal testing of cutaneous sebaceous carcinoma: a missed opportunity in Lynch syndrome detection
|
Rajan, Neil
|
|
|
25 |
1 |
p. e1-e2
|
artikel
|
| 34 |
Utilising cancer registry data to monitor cancer burden
|
Seppä, Karri
|
|
|
25 |
1 |
p. 6-7
|
artikel
|
| 35 |
When less is more—reducing complexity in cancer trials
|
Patel, Timil H
|
|
|
25 |
1 |
p. 10-12
|
artikel
|
Tijdschrift beschrijving